Oncology Grants
In continuation of CHF’s strong support of canine cancer research, the Oncology Research Program Area remains committed to innovative research that will aid in the discovery of advanced diagnostic technology and therapeutic target identification.
To make sense of the complexity of cancer, new approaches are needed to provide comprehensive characterization of tumors and other canine cancers. These approaches will likely require broad bioinformatic analyses, high throughput methodologies and systems biology tools.
Active Grants:
| 03368 | Liquid Biopsy for Early Relapse Detection and Improved Treatment of Canine Mast Cell Tumors |
| 03305-A | TRAF3 as a Novel Prognostic Biomarker in Canine Tumor-associated Macrophages |
| 03283 | Investigating the Immune and Cytoreductive Activities of Gilvetmab Alone and in Combination with Indoleamine 2,3-Dioxygenase Inhibition in Canine Urothelial Carcinoma |
| 03261-A | Mechanisms of Immunotolerance in Canine Oral Melanoma: An Opportunity for Comparative Approaches |
| 03186-A | Comparison of Genomic Mutation Status Between Primary Site and Metastatic Lymph Node in Canine Oral Malignant Melanoma |
| 3195 | Early Genetic Markers of Histiocytic Sarcoma for Faster Diagnosis and More Effective Treatment |
| 03228 | Identification of Tumor-Specific Proteins for Targeted Therapy in Solid and Disseminated Histiocytic Sarcoma |
| 03103 | Identification of Genetic Mutations in AnalSac Carcinoma Development in English Cocker Spaniels, Part II – Validation |
| 03100-A | The Use of Artificial Intelligence and Computed Tomography Image Features to Predict Sentinel Lymph Node Metastasis in Dogs with Oral Tumours |
| 02992-A | Sentinel Lymph Node Mapping for Dogs with Lung Tumors |
| 03009 | Evaluating Accuracy for Identification of Sentinel Lymph Nodes in Dogs with Cutaneous MCT: A Comparison |
| 02987 | It’s All In The Genes: The Mutational Landscape of Acute Myeloid Leukemia in Dogs |
| 02880 | Enhanced Surgical Margin Imaging with Polarization-sensitive Optical Coherence Tomography in Canine Soft Tissue Sarcoma and Mammary Tumors |
| 02732-A | Tumor-educated Platelets: A Novel Minimally Invasive Liquid Biopsy for Early Cancer Diagnosis |
Previously Awarded Grants:
| 02907 | Ultrasound-guided Histotripsy Ablation of Canine Brain Tumors through an Acoustically Transparent Cranial Window |
| 02879 | Use of CRISPR-based Genome-wide Approach for Identification of Vulnerabilities in Canine Oral Melanoma |
| 02855-A | Repurposing Drugs to Modulate Myeloid-derived Suppressor Cells (MDSCs) in Canine Soft Tissue Sarcomas |
| 03019 | Evaluation of a Targeted Anti αvβ3 Integrin Near-InfraRed (NIR-) Dye for Controlled Resection of Naturally Occurring Soft Tissue Sarcomas in Dogs |
| 02910 | Open-Label, Phase-2 Clinical Trial of Chlorambucil and Toceranib for Canine Mast Cell Tumors |
| 03017 | Molecular Characterization of Canine Soft Tissue Sarcomas Using Spatially Defined Proteomics and Transcriptomics |
| 02920 | Continued Investigation into Tumor-permissive Collagen Signatures in Canine Mammary Gland Tumors: Development of Prognostic Markers and Targeted Therapies for Improved Outcomes |
| 02783 | Transcriptional Profiling of Canine Soft Tissue Sarcoma |
| 02780 | Bladder Carcinogen Exposures in Pet Dogs |
| 02858-A | Investigation of Mechanisms of Resistance to Immunotherapy in Dogs with Spontaneous High-grade Glioma |
| 02758 | Optical Coherence Tomography for Margin Evaluation of Canine Skin and Subcutaneous Neoplasms |
| 02663 | Comparative Brain Tumor Consortium (CBTC) Meningioma Pathology Board |
| 02487 | OX40 Checkpoint Molecule Targeted Antibodies for Cancer Immunotherapy in Dogs |
| 02446 | Development of Genetic Biomarkers to Improve Diagnosis and Treatment of Canine Histiocytic Sarcoma |
| 02595-A | Defining the Flow Cytometric Characteristics of Normal and Diseased Canine Spleen and Visceral Lymph Nodes |
| 02643-A | Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity |
| 02321 | Clinical Trial of Procaspase-3 Activator (PAC-1) in Combination with Hydroxyurea for Treatment of Canine Meningioma |
| 02500 | Immune Targeting of the V600E B-Raf Neoantigen in Canine Urothelial Carcinoma |
| 02636-A | Development of RNA in-situ Hybridization to Identify T Regulatory Cells and their Function within the Tumor Microenvironment of Canine Oral Malignant Melanoma |
| 02489 | Tumor-permissive Collagen Signatures in Canine Mammary Gland Tumors: Development of Prognostic Markers and Targeted Therapies for Improved Outcomes |
| 02456-A | The Impact of Intravenous Anesthetic Agents on Canine Natural Killer Cell |
| 02455-A | Identification of genetic mutations in anal sac carcinoma in English Cocker Spaniels |
| 02204-T | Using Enhanced Imaging to Evaluate Tumor Margins for Canine Mammary Cancer and Soft Tissue Sarcoma |
| 02522-A | The Investigation of Lypoxigenase-5 Expression in Canine Normal, Hyperplastic and Neoplastic Urinary Bladder Epithelium |
| 02405-A | Transcriptome Based Diagnostics in Canine Soft Tissue Sarcoma |
The AKC Canine Health Foundation funds research in 23 different Research Program Areas for the health of all dogs. These program areas enable the Foundation to create depth in our research portfolio and help us to be responsive to the health concerns of our constituents.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.
